Search for Clinical Trial Results
Focal Segmental Glomerulosclerosis - 27 Studies Found
Status | Study |
Recruiting |
Study Name: Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children Condition: Focal Segmental Glomerulosclerosis 1 Date: 2014-09-06 Interventions: Device: Liposorber® LA-15 System Liposorber® LA-15 System is an extracorporeal blood purificat |
Completed |
Study Name: A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS) Condition: Primary Focal Segmental Glomerulosclerosis Date: 2012-08-13 Interventions:
|
Completed |
Study Name: Sirolimus for Focal Segmental Glomerulosclerosis Condition: Focal Glomerulosclerosis Date: 2002-06-26 Interventions: Drug: Sirolimus |
Completed |
Study Name: Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis Condition:
Date: 2008-12-02 Interventions: Drug: tripterygium wilfordii (TW) Pre 30mg/d +TW 120 mg/d, po for 12 weeks |
Active, not recruiting |
Study Name: Predictors of Disease Progression in Primary Focal Segmental Glomerulosclerosis Condition:
|
Completed |
Study Name: A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS) Condition: Glomerulosclerosis, Focal Segmental Date: 2013-11-27 Interventions: Drug: Losmapimod Losmapimod (micronized GW856553X) will be supplied as a film coated white, 7 mm round, |
Completed |
Study Name: Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial Condition: Focal Segmental Glomerulosclerosis Date: 2008-12-22 Interventions:
|
Withdrawn |
Study Name: Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5 Condition: Focal Segmental Glomerulosclerosis Date: 2008-12-31 Interventions: Drug: Galactose Oral galactose, 0.2 g/kg/dose twice daily for 28 days |
Recruiting |
Study Name: Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients Condition:
|
Recruiting |
Study Name: A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS Condition: Primary Focal Segmental Glomerulosclerosis Date: 2012-04-05 Interventions: Biological: Rituximab Rituximab will be infused intravenously on Day 1 and Day 15 at a dose of 375 mg/m2 |